Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
10 hedge funds and large institutions have $3.29M invested in Evoke Pharma in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
5% less capital invested
Capital invested by funds: $3.45M → $3.29M (-$157K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$72.4K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.04K |
| 3 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$3.45K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$88K |
| 2 |
Citigroup
New York
|
-$17K |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$4.59K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $1.96M | +$72.4K | +63 | +4% |
|
|
SC
2
Sophrosyne Capital
New York
| $397K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $378K | +$8.04K | +7 | +2% |
|
4
Bank of America
Charlotte,
North Carolina
| $271K | – | – | – |
|
|
LP
5
LMR Partners
London,
United Kingdom
| $187K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $80K | – | – | – |
|
|
U
7
UBS
Zurich,
Switzerland
| $6K | -$4.59K | -4 | -44% |
|
8
Morgan Stanley
New York
| $4K | – | – | – |
|
|
BIM
9
BlackRock Investment Management
Wilmington,
Delaware
| $4K | +$3.45K | +3 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1K | +$1.15K | +1 | New |
|
|
TC
11
TFS Capital
West Chester,
Pennsylvania
| – | -$88K | -73 | Closed |
|
|
12
Citigroup
New York
| – | -$17K | -14 | Closed |
|
EVOK Hedge Fund Activity: Q2 2014 in Review
10 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2014, worth a combined $3.29M — down 4.6% from $3.45M a quarter earlier.
Fund positioning in EVOK was balanced in Q2 2014: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Opaleye Management, adding an estimated $72.4K. The largest seller was TFS Capital, exiting entirely with an estimated $88K sold.
- 10 institutional investors held Evoke Pharma (EVOK) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $3.29M of Evoke Pharma stock for Q2 2014, down 4.6% quarter-over-quarter.
- 2 funds opened new Evoke Pharma positions in Q2 2014 and 2 closed out, a net change of 0 holders.
- The largest Evoke Pharma buyer in Q2 2014 was Opaleye Management, an estimated $72.4K added.
- The largest Evoke Pharma seller in Q2 2014 was TFS Capital, an estimated $88K sold.
Based on aggregated 13F filings for Q2 2014.